Edition:
India

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

133.31USD
20 Jul 2018
Change (% chg)

$-2.22 (-1.64%)
Prev Close
$135.53
Open
$135.31
Day's High
$136.23
Day's Low
$133.30
Volume
191,945
Avg. Vol
489,795
52-wk High
$176.44
52-wk Low
$35.26

Latest Key Developments (Source: Significant Developments)

Sarepta Receives Negative CHMP Opinion For Exondys
Friday, 1 Jun 2018 

June 1 (Reuters) - Sarepta Therapeutics Inc ::AS ANTICIPATED, SAREPTA RECEIVES NEGATIVE CHMP OPINION FOR EXONDYS® (ETEPLIRSEN) TO TREAT PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY IN EUROPE.SAREPTA THERAPEUTICS INC - SAREPTA WILL SEEK RE-EXAMINATION OF OPINION AND REQUEST THAT A SCIENTIFIC ADVISORY GROUP (SAG) BE CONVENED.SAREPTA THERAPEUTICS INC - WILL SEEK RE-EXAMINATION OF OPINION AND REQUEST THAT A SCIENTIFIC ADVISORY GROUP (SAG) BE CONVENED.SAREPTA THERAPEUTICS INC - RE-EXAMINATION PROCESS IS EXPECTED TO BE COMPLETED BY YEAR-END 2018.SAREPTA THERAPEUTICS INC - WILL ALSO REQUEST A SCIENTIFIC ADVISORY GROUP ON DMD BE CALLED.SAREPTA THERAPEUTICS INC - WILL REQUEST A RE-EXAMINATION OF OPINION, WHICH WILL RESULT IN ASSIGNMENT OF A NEW RAPPORTEUR AND CO-RAPPORTEUR.  Full Article

Sarepta Therapeutics Provides FY 2018 Rev Forecast For Exondys 51
Tuesday, 9 Jan 2018 

Jan 8 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS PRE-ANNOUNCES FOURTH QUARTER 2017 REVENUE AND PROVIDES FULL-YEAR 2018 REVENUE GUIDANCE FOR EXONDYS 51® (ETEPLIRSEN), REPRESENTING APPROXIMATELY 100 PERCENT YEAR-OVER-YEAR GROWTH.Q4 REVENUE $57.3 MILLION VERSUS I/B/E/S VIEW $55.8 MILLION.SEES FY 2018 REVENUE $295 MILLION TO $305 MILLION.SAYS FULL-YEAR 2018 EXONDYS 51 REVENUE GUIDANCE OF $295 - $305 MILLION.SAYS ‍FULL-YEAR 2017 EXONDYS 51 UNAUDITED REVENUE OF $154.6 MILLION​.  Full Article

Capital Ventures International Reports 5.4 Pct Passive Stake In Sarepta Therapeutics
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Sarepta Therapeutics Inc ::CAPITAL VENTURES INTERNATIONAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN SAREPTA THERAPEUTICS INC AS OF DECEMBER 11, 2017 - SEC FILING.  Full Article

Sarepta Therapeutics prices $475 million of convertible senior notes due 2024
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics prices $475 million of convertible senior notes due 2024.Sarepta Therapeutics-‍priced $475 million aggregate principal amount of convertible senior unsecured notes that will mature on November 15, 2024​.Sarepta Therapeutics - ‍notes will bear cash interest at a rate of 1.50%, payable on May 15 and November 15 of each year, beginning on May 15, 2018​.  Full Article

Sarepta Therapeutics announces proposed offering of $375 mln of convertible senior notes
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics announces proposed offering of $375 million of convertible senior notes due 2024.Sarepta Therapeutics Inc - ‍Chief Executive Officer indicates interest in purchasing $2 million of shares of Sarepta's common stock​.Sarepta - ‍intends to use a portion of net proceeds from offering to pay cost of certain capped call transactions​.Sarepta - ‍purchase price/share of stock bought by ingram expected to equal closing price/share of co's stock on date of pricing of offering​.  Full Article

Sarepta Therapeutics reports FDA clearance of IND for co's ppmo exon 51 candidate, srp-5051
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics announces FDA clearance of IND for the company's ppmo exon 51 candidate, srp-5051.Sarepta Therapeutics Inc - will immediately initiate its phase 1/2a clinical trial and begin screening patients with dmd amenable to skipping exon 51​.  Full Article

Sarepta Therapeutics says FDA clears gene therapy IND application
Friday, 3 Nov 2017 

Nov 3 (Reuters) - Sarepta Therapeutics Inc -:Sarepta Therapeutics and Nationwide Children’S Hospital announce U.S. Food And Drug Administration (FDA) clearance of the IND application for the GALGT2 gene therapy program.Sarepta Therapeutics- ‍IND application for GALGT2 gene therapy program was cleared by FDA​.Sarepta Therapeutics - Nationwide Children's is on track to initiate Phase 1/2A clinical trial in individuals with DMD by year-end 2017 ​.  Full Article

Sarepta Therapeutics signs exclusive global collaboration with Duke University
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics signs exclusive global collaboration with Duke University for Gene Editing CRISPR/CAS9 technology to develop new treatments for Duchenne Muscular Dystrophy (DMD).Sarepta Therapeutics Inc - ‍financial terms of agreement have not been disclosed​.  Full Article

Sarepta Therapeutics sees FY17 revenue $150 mln to $155 mln
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics announces third quarter 2017 financial results and recent corporate developments.Q3 non-GAAP loss per share $0.20.Q3 earnings per share view $-0.85 -- Thomson Reuters I/B/E/S.Q3 GAAP loss per share $0.78.Sees FY 2017 revenue $150 million to $155 million.Q3 revenue $46 million versus I/B/E/S view $40.8 million.Sarepta Therapeutics Inc - ‍raises annual 2017 revenue guidance to between $150 million and $155 million​.  Full Article

UnitedHealth spokesman confirms plan to cover Sarepta's Exondys 51
Friday, 7 Oct 2016 

UnitedHealth Group Inc : UnitedHealth spokesman confirms plans to cover Sarepta Therapeutics Inc's muscular dystrophy drug Exondys 51. (Reporting by Caroline Humer) ((caroline.humer@thomsonreuters.com;)).  Full Article

Sarepta shares soar as Duchenne gene therapy shows promise

Sarepta Therapeutics' shares jumped 60 percent on Tuesday after promising results from a gene therapy study positioned the specialty drugmaker as a potential leader in the market for Duchenne muscular dystrophy (DMD) treatments.